Evoke Neuroscience

Executive Summary

Evoke Neuroscience is a medical technology company commercializing an FDA-cleared hardware/software system for in-office cognitive function assessment. Its platform integrates quantitative EEG (qEEG) and event-related potential (ERP) biomarkers to aid physicians in early detection and monitoring of cognitive impairment. The system is designed for use in primary care and specialty settings, addressing a growing need for objective, accessible diagnostics in brain health. Founded in 2010 and headquartered in New York, the company operates as a private entity with a focus on expanding adoption among clinicians. While detailed financial and operational metrics are not publicly available, Evoke's FDA-cleared status and relevance to the aging population position it within a promising niche. The company faces competition from other neurodiagnostic tools but differentiates through its integrated biomarker approach and point-of-care applicability.

Upcoming Catalysts (preview)

• Q3 2026FDA clearance for expanded indication (e.g., concussion or dementia)60% success
• Q3 2026Strategic partnership with a large healthcare system for commercialization50% success
• Q3 2026Publication of pivotal clinical data supporting diagnostic accuracy70% success